Theravance Biopharma's total assets for Q3 2024 were $356.11M, a decrease of -1.64% from the previous quarter. TBPH total liabilities were $170.45M for the fiscal quarter, a 1.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.